Haplo ever after: haplo PTCy for children
- PMID: 37756536
- PMCID: PMC10546334
- DOI: 10.1182/bloodadvances.2023010755
Haplo ever after: haplo PTCy for children
Conflict of interest statement
Comment on
-
Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias.Blood Adv. 2023 Sep 26;7(18):5639-5648. doi: 10.1182/bloodadvances.2023010281. Blood Adv. 2023. PMID: 37257193 Free PMC article.
References
-
- O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377–386. - PubMed
-
- Perez-Martinez A, Ferreras C, Pascual A, et al. Haploidentical transplantation in high-risk pediatric leukemia: a retrospective comparative analysis on behalf of the Spanish Working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH) Am J Hematol. 2020;95(1):28–37. - PubMed
-
- Berger M, Lanino E, Cesaro S, et al. Feasibility and outcome of haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide for children and adolescents with hematologic malignancies: an AIEOP-GITMO Retrospective Multicenter Study. Biol Blood Marrow Transplant. 2016;22(5):902–909. - PubMed